Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of September 2026. The report details a warrant inducement transaction entered into on September 14, 2026, with an accredited holder of the Company's outstanding Series M, N, and O warrants. The transaction is expected to close on or about September 15, 2026.
Key Financial Metrics
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report focused on a specific corporate transaction. However, the following financial metrics related to the transaction are disclosed:
- Expected Gross Proceeds: Approximately $2.3 million.
- Shares to be Issued: 2,204,218 American Depositary Shares (ADSs), representing 110,210,900 ordinary shares.
- Transaction Fees: An 8.0% cash fee payable to the warrant solicitation agent, Maxim Group LLC, based on gross proceeds.
- Exercise Price: Reduced to $1.05 per share for the existing warrants being exercised.
Material Changes
The primary material change is the reduction of the exercise price for specific warrant series and the issuance of new replacement warrants:
- Warrant Exercise: The Holder is exercising 282,952 Series M, 701,754 Series N, and 1,219,512 Series O warrants.
- Replacement Warrants: The Holder will receive two Series P Warrants for every Existing Warrant exercised. These new warrants are immediately exercisable and expire five years from issuance.
- Capital Structure: The transaction will increase the Company's outstanding share count by 2,204,218 ADSs upon closing.
Outlook, Risks, and Contingencies
Management commentary is limited to the mechanics of the transaction. Key risks and contingencies include:
- Beneficial Ownership Limitations: If the exercise causes the Holder to exceed beneficial ownership limits, the Company will only issue shares up to the permitted maximum, holding the balance in abeyance until the Holder provides notice of compliance.
- Registration Obligations: The Company must file a resale registration statement within 15 days and use commercially reasonable efforts to make it effective within 45 days of closing.
- Liquidated Damages: The Company is subject to paying liquidated damages if the shares underlying the Series P Warrants are not registered for resale or if restrictive legends are not removed timely.
- Cashless Exercise: If the resale registration is not effective at the time of exercise, the Series P Warrants may be exercised on a cashless basis after six months.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $2.3 million gross proceeds.
- Confirm the effective date of the resale registration statement for the Series P Warrants.
- Monitor for any shares held in abeyance due to beneficial ownership limitations.
- Review the full text of the Warrant Inducement Agreement (Exhibit 10.1) for specific liquidated damages terms.
- Check subsequent filings for the impact of the 2,204,218 new ADSs on total share count and dilution.